EBM Penggunaan HA (Hyaluronic Acid) pada kasus IC (Interstitial Cystitis) /BPS (Bladder Pain Syndrome)

Level Of Grades of
NO Journal Title Design Patient Objective Result Importancy
Evidence Recommendation
1 Barua, JM, A Systematic Meta 801 To compare HMW-HA is superior than ChS "In conclusion, this meta- IA A
Arance I, review and meta- analytic patients the clinical 0.2% and PPS to improve VAS analytical review provides
Angulo, JC, analysis on the review of efficacy of score and the response rate. The evidence of the positive
Riedl, CR. efficacy of BPS/IC currently NNT for a response to effects of intravesical GAG
2015. In intravesical available intravesical therapy ranged therapy for BPS/IC and that
Urogynecol J. therapy for products for between 1.33 (HMW-HA) and this treatment may
10.1007/s0019 bladder pain intravesical 14.81 (ChS 2%), with a significantly improve
2-015-2890-7 syndrome/interstit therapy of negative value for the PPS patients’ symptoms.
ial cystitis BPS/IC and combination therapy. With this If medical and
to assess their low NNT, HMW-HA was also pharmacoeconomic aspects
pharmacoeno significantly superior with are combined, HMW-HA
mic impact. regard to cost-effectiveness and seems to have some
cost efficacy to all other advantage over other
instillation regimes. instillation agents."
2 Engelhardt, Long-term results RCT 70 To find the Forty-eight of 70 patients Besides a high rate of acute IB A
PF, Morakis N, of intravesical patients long term responded after a mean follow- symptom remission,
et al. 2010 hyaluronan of efficacy of up of 4.9 years. The average intravesical hyaluronan also
therapy in bladder BPS/IC intravesical initial VAS score of 8.15 had shows long-term efficacy in
pain hyaluronan been reduced to 2.71 after a considerable number of
syndrome/interstit for bladder therapy and further to 2.14 5 BPS/IC patients and the
ial cystitis pain years later. Fifty percent of therapy has no adverse
syndrome/ patients (24/48) reported effects.
interstitial complete bladder symptom
cystitis remission at 5 years follow-up
(BPS/IC). without any additional therapy;
41.7% (20/48) with symptom
recurrence was improved with
hyaluronan maintenance
therapy.